SERPINE2 inhibits EGFR protein degradation through c-Cbl-mediated ubiquitination in hepatocellular carcinoma and activates the EGFR signaling pathway to promote hepatocellular carcinoma metastasis, whereas inhibition of the SERPINE2–EGFR axis both combats distant metastasis and sensitizes cells to therapeutic agents such as sorafenib [56]. Here, EGFR is linked to hepatocellular carcinoma.